Xtl Biopharmaceuticals (XTLB) Cash from Investing Activities Growth (1y) (2010 - 2016)
Xtl Biopharmaceuticals (XTLB) Cash from Investing Activities Growth (1y) (2010 - 2016) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 62.68% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -674.01% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -166.24% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Xtl Biopharmaceuticals | 2.58 Bn | 2.58 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2016 | 107.14% |
| Dec 31, 2015 | -110.47% |
| Sep 30, 2015 | -154.31% |
| Jun 30, 2015 | -102.60% |
| Dec 31, 2014 | 154.60% |
| Sep 30, 2014 | -96.93% |
| Jun 30, 2014 | 18,033.33% |
| Mar 31, 2014 | -44.42% |
| Dec 31, 2013 | -29.63% |
| Sep 30, 2013 | 2,263.75% |
| Jun 30, 2013 | 99.81% |
| Mar 31, 2013 | -48.83% |
| Dec 31, 2012 | 25.84% |
| Sep 30, 2012 | 6.67% |
| Jun 30, 2012 | -7,147.83% |
| Mar 31, 2012 | 152.97% |
| Dec 31, 2011 | -1,947.92% |
| Sep 30, 2011 | 725.00% |
| Jun 30, 2011 | 560.00% |
| Mar 31, 2011 | -7,023.08% |